Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efzofitimod in Pulmonary Sarcoidosis
NCT05415137Phase 3Completed
- Sponsor
- aTyr Pharma
- Start
- Sep 2022
- Primary completion
- Jun 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 9
01
Overview
A Phase 3 trial of efzofitimod in pulmonary sarcoidosis, sponsored by aTyr Pharma. Started Sep 2022; status: completed.
02
Drugs
efzofitimod
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on NCT05415137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05415137.